Statistics for Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
Total visits
| views | |
|---|---|
| Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial | 43 |
Total visits per month
| views | |
|---|---|
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
File Visits
| views | |
|---|---|
| Brannagan-2020-Early-data-on-longterm-efficacy-and.pdf(legacy) | 56 |
| Brannagan-2020-Early-data-on-longterm-efficacy-and.pdf | 4 |
| Enfermedad de Schilder - dos nuevos casos.pdf(legacy) | 1 |
Top country views
| views | |
|---|---|
| United States | 28 |
| Australia | 5 |
| China | 5 |
| Germany | 1 |
| India | 1 |
| Russia | 1 |
| Singapore | 1 |
| Ukraine | 1 |